Statute treatment: 21 C.F.R. § 320.24

Ranked leading cases interpreting this statute, drawn from 32 citation events across 14 distinct cases.

32citations total

14distinct interpreting cases

5distinct courts

2citations in last 5y

1992–2024year range

Top 11 leading cases

#1 Viropharma Incorporated v. Hamburg (2012) dcd 20 own cites 5× in case

#2 Hill Dermaceuticals, Inc. v. Food & Drug Administration (2013) cadc 85 own cites 1× in case

#3 Astellas Pharma US, Inc. v. Food & Drug Administration (2009) dcd 12 own cites 3× in case

#4 ViroPharma, Inc. v. Hamburg (2011) dcd 6 own cites 5× in case

#5 Bristol-Myers Squibb Co. v. Shalala (1996) dcd 41 own cites 1× in case

#6 Fed. Trade Comm'n v. Shire Viropharma, Inc. (2019) ca3 35 own cites 1× in case

#7 Schering Corp. v. Sullivan (1992) dcd 9 own cites 2× in case

#8 Somerset Pharmaceuticals, Inc. v. Shalala (1997) ded 4 own cites 2× in case

#9 1199seiu Nat'l Benefit Fund v. Allergan, Inc. (In re Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litig.) (2018) nyed 4 own cites 1× in case

#10 Nostrum Pharmaceuticals LLC v. FDA (2022) cadc 3 own cites 1× in case

#11 Viropharma Inc. v. Hamburg (2012) cadc 4 own cites 1× in case

Ranking method: leading_score = ln(1 + own_citation_count) × √(mentions_in_case) × flag_factor, where flag_factor = 1.0 green · 0.6 unknown · 0.5 neutral · 0.4 yellow · 0.3 procedural · 0 red. Red-flagged cases excluded — their interpretation has been undermined and shouldn't lead the list. Top 20 returned per statute. Open any case for full G Cite, trajectory, and per-circuit treatment.